Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 4/20 | 0.40 |
| ▸ | RARA | P10276 | 4/20 | 0.40 |
| ▸ | RARG | P13631 | 4/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178123 | 0.86 | MEN1 (0.51) | MEN1KMT2APOLBGAAGFER | |
| SCHEMBL7687459 | 0.82 | MEN1 (0.59) | MEN1KMT2APOLBGAAGFER | |
| SCHEMBL2420330 | 0.81 | MEN1 (0.50) | MEN1KMT2APOLBGAAGFER | |
| SCHEMBL548708 | 0.80 | MEN1 (0.73) | MEN1KMT2APOLBGAAGFER | |
| SCHEMBL11702433 | 0.79 | CNR2 (0.51) | MEN1KMT2APOLBGAAGFER | |
| SCHEMBL8795602 | 0.79 | MEN1 (0.47) | MEN1KMT2APOLBGAAGFER | |
| SCHEMBL26272370 | 0.79 | MEN1 (0.36) | MEN1KMT2APOLBGAAGFER | |
| SCHEMBL27217482 | 0.79 | MEN1 (0.39) | MEN1KMT2APOLBGAAGFER | |
| SCHEMBL548836 | 0.78 | MEN1 (0.53) | MEN1KMT2APOLBGAAGFER | |
| SCHEMBL14627878 | 0.78 | RARB (0.44) | MEN1KMT2APOLBGAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992094-B1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-31 | — | — | US | disclosed |
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-19 | — | — | US | disclosed |
| US-6921777-B2 | Heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-26 | — | — | US | disclosed |
| EP-1086080-B1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2004-08-25 | — | — | EP | disclosed |
| US-20030012803-A1 | Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-01-16 | — | — | US | disclosed |
| US-6444709-B1 | SKIN DISORDERS; ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2002-09-03 | — | — | US | disclosed |
| EP-0986537-B1 | NOVEL HETEROETHYNYLENE COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RES & DEV (FR) | 2002-08-07 | — | — | EP | disclosed |
| EP-1086080-A1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2001-03-28 | — | — | EP | disclosed |
| EP-0986537-A2 | NOVEL HETEROETHYNYLENE COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | Galderma Research & Development, S.N.C. (FR) | 2000-03-22 | — | — | EP | disclosed |
| WO-1999065872-A1 | DIARYLSELENIDE COMPOUNDS AND THEIR USE IN HUMAN OR VETERINARY MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1999-12-23 | — | — | WO | disclosed |
| US-5567721-A | AROMATIC UREA COMPOUND FOR SKIN DISORDER, RHEUMATIC DISEASE, RESPIRATORY DISORDER AND EYE DISORDER | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES (FR) | 1996-10-22 | — | — | US | disclosed |
| WO-1996020938-A1 | ACETYLENES DISUBSTITUTED WITH 2-TETRAHYDROPYRANOXYARYL AND ARYL OR HETEROARYL GROUPS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-07-11 | — | — | WO | disclosed |
| WO-1996020937-A1 | ACETYLENES DISUBSTITUTED WITH HYDROXYARYL AND ARYL OR HETEROARYL GROUPS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1996-07-11 | — | — | WO | disclosed |
| US-5534641-A | Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity | ALLERGAN | 1996-07-09 | — | — | US | disclosed |
| US-5498795-A | ANTITUMOR AGENTS, SKIN DISORDERS, ATHEROSCLEROSIS, PROSTATE CANCER AND AUTOIMMUNE DISEASES | ALLERGAN, INC. (US) | 1996-03-12 | — | — | US | disclosed |
| US-5439925-A | Skin disorders, rheumatic diseases | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-08-08 | — | — | US | disclosed |
| US-5387594-A | Administering for topical and systemic treatment of | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1995-02-07 | — | — | US | disclosed |
| EP-0552282-B1 | BI-AROMATIC COMPOUNDS AND THEIR USE IN HUMAN AND VETERINARY MEDECINE AND IN COSMETIC PREPARATIONS | CIRD GALDERMA (FR) | 1994-08-24 | — | — | EP | disclosed |
| EP-0552282-A1 | BI-AROMATIC COMPOUNDS AND THEIR USE IN HUMAN AND VETERINARY MEDECINE AND IN COSMETIC PREPARATIONS. | CIRD GALDERMA (FR) | 1993-07-28 | — | — | EP | disclosed |
| WO-1992006948-A1 | BI-AROMATIC COMPOUNDS AND THEIR USE IN HUMAN AND VETERINARY MEDECINE AND IN COSMETIC PREPARATIONS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030012803-A1 | Novel heteroethynylenic compounds and pharmaceutical and cosmetic compositions containing them | TYR, CYP1B1, MITF | MEN1 1151/4885KMT2A 4222/4885POLB 1813/4885 |
| US-20060014803-A1 | Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics | TYR, DERL1, GPX1 | MEN1 1322/4885KMT2A 2169/4885POLB 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.